/
Oncology
Non-Small Cell Lung Cancer
494
Pipeline Programs↗
826
Active Trials↗
282
Companies Involved↗
Non-Small Cell Lung Cancer is a highly competitive landscape with 494 programs across 282 companies. The most active players are AstraZeneca, Shanghai Henlius Biotech, Sichuan Baili Pharmaceutical Co., Ltd.. 168 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical96
Phase 161
Phase 2169
Phase 3168
Approved
No programs
Analysis
Modality Breakdown
83%
Small molecule
372 of 447 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 447 classified programs, each share of the total. Modality classified for 95% of 494 pipeline programs.
Analysis
Trial Status
2,860
clinical trials
Completed1,165 · 41%
Recruiting407 · 14%
Terminated393 · 14%
Unknown status342 · 12%
Active, not recruiting255 · 9%
Not yet recruiting158 · 6%
Other140 · 5%
Clinical Trials
Trial Activity
2860 trials
Page 1 of 191
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)